Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

OSTXBullishCorporate Developmentsnews

High materiality9/10

OSTX OST-HER2 Phase 2b shows strong 3-year survival; regulatory path accelerates

Oct 6, 2026, 3:01 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong efficacy signals and broad regulatory milestones support upside; immediate price reaction was modestly negative, typical for micro-caps on news flow; longer-term catalysts suggest upside potential.

AI summary

What happened, with direct paths to the underlying reporting

OS Therapies reports statistically significant three-year overall survival gains with OST-HER2 in osteosarcoma patients post-resection, with 72.7% versus 45.8% historical control. WHO approved the brand name Herlystic, and OSTX aims to file early market access submissions in the US, UK, Europe, and Australia in Q4 2026. A Rare Pediatric Disease voucher could add strategic value if granted.

OSTX OST-HER2 shows 3-year OS of 72.7% vs 45.8% historical.
WHO accepts brand name Herlystic for OST-HER2.
OSTX holds Orphan Drug, Fast Track, Rare Pediatric Disease designations.
Plans for US/UK/Europe/Australia market submissions in Q4 2026.
OSTX stock down 2.19% to $1.56.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.